Faeth Therapeutics Inc. (FTH) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, FTH scores 29 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars, each weighted at 20 points:

• Fundamental Cash Engine (6 / 20): Per the RQD rating, ROIC is -35% and FCF yield is -4.22%. For a prospective investor, this indicates the business is currently consuming capital rather than generating returns on it, which removes the cash-flow support that typically anchors valuation.
• Whale 13F Flow (4 / 20): The RQD rating reflects weak institutional accumulation and options positioning. Limited smart-money conviction means fewer large holders are signaling confidence in the thesis.
• Insider Conviction (3 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow is scored at 3 / 20, the lowest pillar. Weak insider conviction is an educational red flag: those closest to the company are not visibly betting on the upside.
• Macro Regime Fit (6 / 20): The RQD rating records a beta of 1.0 and sector sensitivity as the basis for this score. FTH moves in line with the broader market, so it offers no defensive cushion and no obvious macro tailwind.
• Forensic Balance Sheet (10 / 20): Per the RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. The Z-score sits in a zone that warrants monitoring, while the Piotroski score signals weak fundamental quality. This is the strongest pillar, but it is still only half-credit.

Investor implications: The upside case rests almost entirely on a future operating turnaround or a pipeline event that the source data does not quantify. Valuation tradeoffs are stark: with negative ROIC and negative FCF yield, traditional earnings-based multiples cannot be applied, so the market price reflects expectations rather than current cash generation. The stock's 52-week range of $7.45 - $42.14 illustrates very high price volatility, meaning both sharp rallies and drawdowns are plausible. The overall RQD profile points toward caution and avoidance rather than accumulation.

Per the SEC financials, the company reported operating losses in every period provided, with losses narrowing from $-37.1M in FY 2023 to $-22.3M in FY 2025. Gross, operating, and net margins are each recorded as 0% in the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, per the Roarable RQD rating. Cash declined from $10.0M to $8.7M between FY 2024 and FY 2025, and debt is reported as N/A across the periods, with Debt/Equity of 0.5 per the RQD rating.

Per the news feed, FTH has six recent items, all rated YELLOW under the MARKET WIRE impact label:

• Seasonal returns chart coverage (Yahoo Finance UK).
• Estimates coverage (TradingView).
• Announcement of inducement grants under Nasdaq Listing Rule 5635(c)(4), dated October 22, 2026 (BioSpace). Inducement grants are equity awards made to new hires as an inducement to join, and are typically exempt from shareholder approval.
• A reiteration of a stock rating by Citizens on cancer drug potential (Investing.com).
• A speculative biotech mention in a weekly stock picks column (NKyTribune).
• Analyst insights on healthcare companies including FTH (The Globe and Mail).

Risk watch items: the news wire contains no quantified earnings, trial readout, or financing details. The Butterfly Supply-Chain Graph reports no proprietary signals and no links.

• What specific products or drug candidates does Faeth Therapeutics develop, and what is their clinical or regulatory stage?
• How much cash runway remains given FY 2025 operating losses of $-22.3M against reported cash of $8.7M, and will additional financing or dilution be required?
• What drove the change in cash reported for FY 2023, where cash is recorded as N/A?
• What is the company's debt position, since debt is reported as N/A while Debt/Equity is listed at 0.5?
• What do the inducement grants announced on October 22, 2026 imply about hiring plans and equity dilution?